TALE-Nuclease STAT3 Gene Integration for HIES
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current gene therapy approaches fail to effectively treat Hyper-IgE syndrome (HIES) due to the complexity of expressing STAT3α and STAT3β isoforms in a controlled and balanced manner, particularly given the dominant-negative effects and haploinsufficiency caused by mutations in the STAT3 gene.
Innovation Solution
The development of a gene editing method using TALE-nucleases to specifically target and correct mutations in the STAT3 gene in hematopoietic stem cells (HSCs) or T-cells, integrating a functional STAT3 sequence that enables alternative splicing and expression of both STAT3α and STAT3β isoforms, thereby restoring normal cellular function.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If allogeneic hematopoietic stem cell transplantation is performed to treat HIES, then the genetic defect can be corrected, but severe side effects such as graft-versus-host disease occur
Solution Approach 1:
The patent converts the harmful approach of allogeneic transplantation into a beneficial autologous gene therapy approach. By using the patient's own HSCs that have been genetically corrected ex vivo, the therapy achieves the benefit of genetic correction while eliminating the harm of graft-versus-host disease and other transplantation-related complications
Solution Approach 2:
The patent introduces an intermediary step of ex vivo gene correction as a mediator between the patient's diseased cells and the healthy state. The HSCs are harvested, genetically corrected outside the body using gene editing technologies, and then returned to the patient, avoiding direct transplantation of allogeneic cells and their associated harms
2Reliability
If gene addition therapy is used to replace missing STAT3 function, then STAT3 deficiency can be corrected, but controlled and balanced expression of STAT3α and STAT3β isoforms cannot be achieved
Solution Approach 1:
The patent applies preliminary action by using gene editing technologies to correct the endogenous STAT3 gene before it undergoes transcription and translation. By correcting the DNA sequence in advance, the natural transcriptional and translational machinery automatically produces the correct isoform balance without requiring complex external control systems
Solution Approach 2:
The patent uses gene editing to create a corrected copy of the endogenous STAT3 gene within the patient's own genome. This corrected copy replaces the defective gene and restores normal function through the cell's existing regulatory mechanisms, avoiding the complexity of introducing entirely new transgenic expression systems
3Manufacturing precision
If TALE-nucleases are used to target and correct STAT3 mutations, then precise gene correction is achieved, but the complexity of delivering and expressing TALE-nuclease components increases
Solution Approach 1:
The patent segments the gene editing system into modular components: TALE-nuclease proteins or their encoding sequences are delivered separately from the donor DNA template. This segmentation allows each component to be optimized and controlled independently, managing the overall system complexity while maintaining high correction precision
Solution Approach 2:
The patent uses intermediary vectors or delivery systems to transport the TALE-nuclease components and donor DNA into the HSCs. These intermediaries facilitate the delivery process and can be removed or degraded after serving their function, reducing the long-term complexity burden in the target cells
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for the therapeutic correction of STAT3 gene function in HSCs or T-cells, leading to the expression of functional STAT3 isoforms and potentially alleviating the symptoms of Hyper-IgE syndrome by enhancing the immune system's ability to fight infections.
Implementation Method 1
gene editing reagents, such as TALE-nucleases, that specifically target the endogenous STAT3 gene
Implementation Method 2
exogenous polynucleotide sequence being integrated in an endogenous STAT3 gene
Implementation Method 3
restoring the normal cellular phenotype by enabling alternative splicing and hence expression of both STAT3 isoforms
Data Source
AI summary
The present invention generally relates to the field of genome engineering (gene editing), and more specifically to gene therapy for the treatment of Hyper-lgE syndrome (HIES). In particular, the present invention provides means and methods for genetically modifying HSCs or T-cells involving gene editing reagents, such as TALE-nucleases, that specifically target an endogenous STATS gene comprising at least one mutation causing Hyper-lgE syndrome (HIES), thereby allowing the restoration of the normal cellular phenotype. The present invention also provides populations of engineered HSCs or T-cells which comprise cells comprising an exogenous polynucleotide sequence comprising at least a partial or complete sequence of a functional STATS gene, said exogenous polynucleotide sequence being integrated in an endogenous STATS gene comprising at least one mutation causing Hyper-lgE syndrome (HIES), resulting in the expression of a functional STATS polypeptide. The present invention further provides pharmaceutical compositions comprising the cell populations of the invention, and their use in gene therapy for the treatment of Hyper-lgE syndrome (HIES).